邱 宗傑

Medicine & Life Sciences

1. Hematopoietic Stem Cell Transplantation 100%
2. Taiwan 96%
3. Non-Hodgkin's Lymphoma 41%
4. Survival 40%
5. Rituximab 36%
6. Lymphoma, Large B-Cell, Diffuse 36%
7. Lymphocyte Count 35%
8. Graft vs Host Disease 34%
9. Neoplasms 34%
10. Multiple Myeloma 33%
11. Transplantation 30%
12. Drug Therapy 29%
13. Lymphoma 29%
14. Transplants 26%
15. Precursor Cell Lymphoblastic Leukemia-Lymphoma 25%
16. Incidence 24%
17. B-Cell Lymphoma 22%
18. Hematologic Neoplasms 19%
19. Hematopoietic Stem Cells 19%
20. T-Cell Lymphoma 18%
21. Fetal Blood 18%
22. Stem Cell Transplantation 18%
23. Myelodysplastic Syndromes 18%
24. Paroxysmal Hemoglobinuria 17%
25. Leukemia, Myelogenous, Chronic, BCR-ABL Positive 17%
26. Candidemia 17%
27. Aplastic Anaemia 17%
28. Cancer Pain 16%
29. Bone Marrow 15%
30. Oxaliplatin 15%
31. Fish Oils 15%
32. Therapeutics 15%
33. Mortality 15%
34. Colorectal Neoplasms 15%
35. Vincristine 15%
36. Salvage Therapy 15%
37. Stem Cells 15%
38. Pericardial Effusion 15%
39. Tissue Donors 15%
40. Unrelated Donors 14%
41. Thiotepa 14%
42. Selenium 14%
43. Hepatitis B 14%
44. Busulfan 14%
45. Fentanyl 13%
46. Infections 13%
47. Hepatitis B virus 13%
48. Doxorubicin 13%
49. Progression-Free Survival 13%
50. Carcinoma 12%